Ranibizumab

Biochem/physiol Actions KY-05009 is a Traf2- and Nck-interacting kinase (TNIK) inhibitor that inhibits the epithelial-to-mesenchymal transition (EMT) in cancer cells. KY-05009 is also known as (5-(4-methylbenzamido)-2-(phenylamino)

Licochalcone E, a flavonoid compound isolated from Glycyrrhiza uralensis , inhibits NF-κB and AP-1 transcriptional activity through the inhibition of AKT and MAPK activationForm:SolidIC50&amp: Target:AKT, MAPK, NF-κB.

Licochalcone E, a flavonoid compound isolated from Glycyrrhiza uralensis , inhibits NF-κB and AP-1 transcriptional activity through the inhibition of AKT and MAPK activationForm:SolidIC50&amp: Target:AKT, MAPK, NF-κB.

InformationLorlatinib (PF-6463922) Lorlatinib (PF-6463922) is a potent, dual ALK/ROS1 inhibitor with K i of &lt:0.02 nM, &lt:0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. PF-06463922 induces apoptosis . Phase

Lutikizumab (anti-IL1a&IL1b).

Lutikizumab (anti-IL1a&IL1b).

InformationMomelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor ofJAK1/JAK2withIC50of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) inducesapoptosisandautophagy. Phase 3.In vitroCYT387 inhibits the

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC 50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC 50 =155 nM).In VitroMomelotinib sulfate (CYT387 sulfate salt) inhibits growth of Ba/F3- JAK2 V617F

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC 50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC 50 =155 nM).In VitroMomelotinib sulfate (CYT387 sulfate salt) inhibits growth of Ba/F3- JAK2 V617F

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC 50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC 50 =155 nM).In VitroMomelotinib sulfate (CYT387 sulfate salt) inhibits growth of Ba/F3- JAK2 V617F

General description DNA damage and/or hyperproliferative signals activate wildtype p53 tumor suppressor protein (TP53: MIM 191170), inducing cell cycle arrest or apoptosis. Mutations that inactivate p53 occur in 50% of all tumors.

General description DNA damage and/or hyperproliferative signals activate wildtype p53 tumor suppressor protein (TP53: MIM 191170), inducing cell cycle arrest or apoptosis. Mutations that inactivate p53 occur in 50% of all tumors.